Cardiology Research and Practice / 2016 / Article / Tab 2

Clinical Study

Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure

Table 2

Flow-mediated dilatation and blood lipids.

Baseline12 weeks16 weeks

FMD [%]
 Rosuvastatin7.56 ± 1.61
 Placebo4.73 ± 0.884.74 ± 1.015.14 ± 0.68
LDL [mmol/L]
 Rosuvastatin3.30 ± 0.17
 Placebo3.91 ± 0.273.12 ± 0.363.31 ± 0.45
HDL [mmol/L]
 Rosuvastatin1.17 ± 0.101.26 ± 0.081.16 ± 0.09
 Placebo1.21 ± 0.121.19 ± 0.101.28 ± 0.14

Repeated measures ANOVA for baseline versus 12 weeks.
Repeated measures ANOVA for 12 weeks versus 16 weeks.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.